PPRI Pharma Profile

Country 2023

PPRI Pharma Profile Country

Template

Update: 2023

**PPRI Representatives**Institution 1: Name of person 1 involved in PPRI network, Name of person 2  
Institution 2: Name of person 1 involved in PPRI network, Name of person 2

**Authors**  
Institution 1: Name of author 1, Name of author 2  
Institution 2: Name of author 1, Name of author 2

**Editors**  
Institution 1: Name of editor 1, Name of editor 2  
Institution 2: Name of editor 1, Name of editor 2

**Disclaimer**  
The data provided in this document by the members of the PPRI network and other authors represent the current situation. The data have no legally binding value and are meant especially for the information of PPRI network members who are committed to sharing information on pharmaceutical pricing and reimbursement.

# Acknowledgements

Please add text.

# Introduction

**PPRI reporting systems on pharmaceutical pricing and reimbursement**

**PPRI reporting systems on pharmaceutical pricing and reimbursement**

Accurate and up-to-date country information is of key importance for decision makers and researchers. As the level of detail they are interested in may vary, different reporting formats are useful.

To respond to this need, the PPRI Secretariat developed the PPRI Pharma Profiles as well as further reporting systems as tools for understanding, collecting and analysing pricing and reimbursement information on medicines (and medical devices).

PPRI Pharma Profiles and other reports are written by members of the PPRI network, including national country experts, such as staff of competent authorities for pharmaceutical pricing and reimbursement (Ministries of Health, Medicines Agencies, Social Health Insurance institutions).

Between 2005 and 2023, 35 PPRI Pharma Profiles, 19 PHIS Hospital Reports, 9 PPRI / PHIS Pharma Profiles, 5 PPRI Pharma Briefs and 1 PPRI Medical Devices Brief (France) were produced. The different deliverables (of different lengths and with specific focus) highlight the variety of reporting tools.

All published country reports and profiles are publicly accessible at <https://ppri.goeg.at/ppri_country_information>.

This PPRI Pharma Profile on <Name of country> offers up-to-date information as of 2023 (or latest available year) on pharmaceutical pricing and reimbursement in both the outpatient and inpatient sectors.

**Quality assurance**

All PPRI Pharma Profiles and similar reports are based on a template which provides a standardised outline for each of the reporting tools (accessible at: <https://ppri.goeg.at/methodology_documents>).

Editorial guidelines provide advice to authors and reviewers and aim to increase the readability of the profiles. Readers can expect a universal approach with regard to citations, data presentations, spelling etc. across the PPRI Pharma Profiles and reports.

To achieve clarity for authors, reviewers and readers and thus to create a common understanding of the concepts and terms used, a glossary of pharmaceutical terms has been developed. The most updated version of the Glossary of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies can be found at <https://ppri.goeg.at/ppri-glossary>.

All PPRI Pharma Profiles and further reports are subject to review processes by the PPRI Secretariat and/or PPRI network members.

**About PPRI**

Pharmaceutical Pricing and Reimbursement Information (PPRI) dates back to a research project (2005-2007), co-funded by the European Commission, Directorate-General Public Health and Consumers and the Austrian Federal Ministry of Health, Family and Youth. It was managed by the Austrian National Public Health Institute (Gesundheit Österreich GmbH / GÖG) supported by the WHO Regional Office for Europe. In the course of the project, the PPRI network was established and a set of pharmaceutical indicators, filled with real data from 27 PPRI countries as well as more than 20 country reports (PPRI Pharma Profiles) and brief overviews on the pharmaceutical systems (country information), were produced.

The PPRI project has proved long-term sustainability.

Nearly two decades later, PPRI is a networking and information-sharing initiative on burning issues of pharmaceutical policies from a public health perspective. The PPRI network involves representatives from around 90 institutions: These are public authorities and third party payers from 50 countries (mainly European countries, including all 27 EU Member States) as well as European and international institutions such as European Commission services and agencies, OECD, WHO (HQ and Regional Office for Europe) and World Bank.

In the on-going PPRI initiative, the networking of the public authorities continues via regular networking meetings and continuous sharing of relevant information for decision-making, including updates of country-specific information. The PPRI secretariat is hosted at the Pharmacoeconomics Department of (GÖG). The Department has also been nominated as a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies.

# Guide for authors

When completing the PPRI Pharma Profile template, please consider the following points:

*General*

* For every heading, please give a country-specific overview. The questions below the headings should be seen as a writing support. In case that some of the questions are not applicable to your country, you can ignore them.
* Though the template is based on a list of bullet points with questions and explanatory remarks, **it is important to write a full descriptive text**. Please, do not answer with yes and no. **Questions shall be deleted for the final version.** Please insert cross-references to other sections / chapters if appropriate.
* Please fill the information for yellow marked sections.

*Data source*

* Please provide data using national / local sources (e.g. local health statistical yearbooks, annual reports). Alternatively please use standardised sources, preferably EUROSTAT or OECD data.
* You might also find relevant information in WHO HiT Profiles or in some sections of the PPRI Pharma Profiles, PHIS Hospital Pharma reports, PPRI/PHIS Pharma Profiles and PPRI Pharma Briefs (see <https://ppri.goeg.at/ppri_pharma_profiles>).
* Please also note that for some tables we ask you to fill in OECD data.

*Glossary*

* The authors are kindly asked to use the terms and concepts as defined in the glossary on pharmaceutical terms of the Vienna WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies available at <http://ppri.goeg.at> 🡪 Glossary.
* Note: Some definitions provided in the Glossary may be different than those used in your country. Please use the preferred terms from the glossary or describe the meaning of the term used in your country.

*Tables / Figures*

* Please provide data preferably in national currency unit (NCU) in the tables – and indicate the name of the currency used in the tables. In the text of the profile, please provide data in NCU and Euro (NCU / €) and use the relevant exchange rates for the respective years as listed at the website of the European Central Bank, see: <http://sdw.ecb.int/home.do> --> exchange rates.
* If possible, always provide absolute figures. However, if data is not available give estimation wherever possible (e.g. share in %)
* Please do not delete rows in tables but rather state: not available (= data cannot be provided) or not applicable (= data do not exist).
* Please state for each table / figure which source, including the year, you have used.
* Please have a look at the notes below the table if data at a given point in time should be provided at 31 December or 1 January. Annual data (e.g. prescription, consumption, sales) cover the whole year.

*Citation*

* Please use the Vancouver Referencing System whereby citations are made within the text or as source under the tables in parentheses e.g. (GÖG 2023) and the full references listed alphabetically in the section Bibliography.
* For legislations please use a short title when writing the text. The long title should be mentioned in the bibliography

*Abbreviation*

* Please include all the abbreviations used in the PPRI Pharma Profile in the list of abbreviations. Please use abbreviations only when it approves readability of the text.

**Contact**

If you have any questions, please do not hesitate to contact the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies at the Austrian National Public Health Institute (GÖG).

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies  
Gesundheit Österreich GmbH / Austrian National Public Health Institute (GÖG)  
Stubenring 6, 1010 Vienna, Austria  
Email: [ppri@goeg.at](mailto:ppri@goeg.at), [alexander.haasis@goeg.at](mailto:alexander.haasis@goeg.at) , [nina.zimmermann@goeg.at](mailto:nina.zimmermann@goeg.at)   
Tel.: + 43 1 51561 – 0 (Nina Zimmermann) or 230 (Alexander Haasis)  
URL: <http://ppri.goeg.at>

**Table of content**

[Acknowledgements III](#_Toc112133339)

[Introduction III](#_Toc112133340)

[Guide for authors V](#_Toc112133341)

[List of tables X](#_Toc112133342)

[List of abbreviations XI](#_Toc112133343)

[1 Health care system 13](#_Toc112133344)

[1.1 Population and age structure 13](#_Toc112133345)

[1.2 Organisation of the health care system 13](#_Toc112133346)

[1.3 Health expenditure 14](#_Toc112133347)

[1.4 Sources of funding 15](#_Toc112133348)

[2 Pharmaceutical system 16](#_Toc112133349)

[2.1 Organisation of the pharmaceutical system 16](#_Toc112133350)

[2.2 Availability of and access to medicines 20](#_Toc112133351)

[2.3 Development of the pharmaceutical sales 20](#_Toc112133352)

[2.4 Pharmaceutical consumption 21](#_Toc112133353)

[2.5 Generics 21](#_Toc112133354)

[2.6 Top 10 medicines 22](#_Toc112133355)

[2.7 Market players 24](#_Toc112133356)

[2.8 Pharmaceutical expenditure 25](#_Toc112133357)

[2.9 Sources of funding 26](#_Toc112133358)

[3 Pricing, reimbursement and volume control in the outpatient sector 27](#_Toc112133359)

[3.1 Organisation of the outpatient sector 27](#_Toc112133360)

[3.2 Pricing of medicines 27](#_Toc112133361)

[3.2.1 Pricing policies 27](#_Toc112133362)

[3.2.2 Pricing Policies 28](#_Toc112133363)

[3.2.3 Specific pricing policies 30](#_Toc112133364)

[3.2.4 Discounts / rebates 30](#_Toc112133365)

[3.2.5 Remuneration of wholesalers and community pharmacies 31](#_Toc112133366)

[3.2.6 Taxes 31](#_Toc112133367)

[3.3 Reimbursement of medicines 32](#_Toc112133368)

[3.3.1 Reimbursement policies 32](#_Toc112133369)

[3.3.2 Reimbursement procedure 32](#_Toc112133370)

[3.3.3 Reference price system 32](#_Toc112133371)

[3.3.4 Private pharmaceutical expenses 33](#_Toc112133372)

[3.4 Volume control 34](#_Toc112133373)

[3.4.1 Generic substitution 34](#_Toc112133374)

[3.4.2 Biosimilar substitution 34](#_Toc112133375)

[3.4.3 INN prescribing 35](#_Toc112133376)

[3.4.4 Other generic and biosimilar promotion 35](#_Toc112133377)

[3.4.5 Claw-backs and paybacks 35](#_Toc112133378)

[3.4.6 Managed-entry agreements 35](#_Toc112133379)

[3.5 Evaluation 36](#_Toc112133380)

[3.5.1 Prescription monitoring 36](#_Toc112133381)

[3.5.2 Pharmaceutical consumption monitoring 37](#_Toc112133382)

[3.5.3 Decision making tools 37](#_Toc112133383)

[4 Pricing, reimbursement and volume control in the inpatient sector 38](#_Toc112133384)

[4.1 Organisation of the in-patient sector 38](#_Toc112133385)

[4.2 Pricing and purchasing policies 38](#_Toc112133386)

[4.3 Procurement 39](#_Toc112133387)

[4.4 Reimbursement 39](#_Toc112133388)

[4.4.1 Hospital pharmaceutical formularies 40](#_Toc112133389)

[4.4.2 Pharmaceutical and Therapeutic Committees 40](#_Toc112133390)

[4.5 Volume Control in the in-patient sector 40](#_Toc112133391)

[4.5.1 Monitoring 40](#_Toc112133392)

[4.5.2 Decision-making tools 41](#_Toc112133393)

[4.5.3 Evaluation of measures 41](#_Toc112133394)

[4.5.4 Reports and results 41](#_Toc112133395)

[4.5.5 Interface management 42](#_Toc112133396)

[5 Developments 43](#_Toc112133397)

[6 Bibliography 44](#_Toc112133398)

[6.1 Literature 44](#_Toc112133399)

[6.2 Legislation 45](#_Toc112133400)

[6.3 Web links 45](#_Toc112133401)

# List of tables

[Table 1.1: Country – Demographic indicators 2012, 2017, 2022 13](#_Toc112133402)

[Table 1.2: Country – Health expenditure 2012, 2017, 2022 14](#_Toc112133403)

[Table 2.1: Country – Legal basis and actors (authorities and market players) of the pharmaceutical system, 2023 18](#_Toc112133404)

[Table 2.2: Country – Annual prescriptions in the outpatient sector 2012, 2017, 2022 20](#_Toc112133405)

[Table 2.3: Country – Number of new molecular entities, 2012-2022 20](#_Toc112133406)

[Table 2.4: Country – Annual pharmaceutical consumption 2012, 2017, 2022 21](#_Toc112133407)

[Table 2.5: Country – Development of the generic shares in volume and value, 2012, 2022 22](#_Toc112133408)

[Table 2.6: Country – Top 10 active ingredients in value and volume in the outpatient sector, 2022 23](#_Toc112133409)

[Table 2.7: Country – Top 10 active ingredients in value and volume in the inpatient sector, 2022 23](#_Toc112133410)

[Table 2.8: Country – Retailers of medicines 2012, 2017, 2022 24](#_Toc112133411)

[Table 2.9: Country – Total pharmaceutical expenditure 2012, 2017, 2022 25](#_Toc112133412)

[Table 3.1: Country – Ways of pricing of medicines at manufacturer level, 2023 28](#_Toc112133413)

[Table 3.2: Country – Pricing policies, 2023 29](#_Toc112133414)

[Table 3.3: Country – Regulation of wholesale and pharmacy remuneration, 2023 31](#_Toc112133415)

[Table 3.4: Country – Out-of-pocket payments for medicines, 2023 33](#_Toc112133416)

[Table 4.1: Most important changes in the outpatient and inpatient sectors from 2012 onwards 43](#_Toc112133417)

# List of abbreviations

*Please add abbreviations used in this PPRI Pharma Profile and delete those you did not use!*

ATC Anatomic therapeutic chemical classification

BASG - AGES Bundesamt für Sicherheit im Gesundheitswesen - AGES Medizinmarktaufsicht / Austrian Federal Office for Safety in Health Care - Austrian Medicines and Medical Devices Agency

BMSGPK Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz / Federal Ministry for Social Affairs, Health; Care and Consumer Protection

DRG Diagnosis related group(s)

INN International Non-proprietary Name

FOPI Forum der forschenden phamazeutischen Industrie / Association of research oriented manufacturers

GDP Gross domestic product

GÖG Gesundheit Österreich GmbH / Austrian National Public Health Institute

GP General practitioner

HTA Health technology assessment

HE Health expenditure

HiT Health systems in transition

HOM Hospital-only medicine(s)

HPF Hospital pharmaceutical formulary/ies

NCU National currency unit

NHS National health service

NME New molecular entities

NPM Non-prescription medicine(s)

Mio. Million

OECD Organisation for Economic Co-operation and Development

ÖGV Österreichischer Generikaverband / Austrian Generics Industry Associations

OPP Out-of-pocket payment

PHIS Pharmaceutical Health Information System

PE Pharmaceutical expenditure

POM Prescription-only medicine

PPP Purchasing power parities

PPRI Pharmaceutical Pricing and Reimbursement Information project

PRP Pharmacy retail price

QALY Quality adjusted life year

SHI Social health insurance

THE Total health expenditure

TPE Total pharmaceutical expenditure

VAT Value added tax

VHI Voluntary health insurance

WHO World Health Organisation

# Health care system

This section gives a brief introduction to the demographic and economic situation of the country as well as on the access to the health care system as 2023.

## Population and age structure

Please complete [Table 1.1](#Table11) and comment on the trends regarding population and age structure as well as health status.

Table 1.1:  
Country – Demographic indicators 2012, 2017, 2022

|  |  |  |  |
| --- | --- | --- | --- |
| Demography | 2012 | 2017 | 2022 |
| Total population |  |  |  |
| Population aged 0-14 |  |  |  |
| Population aged 15-64 |  |  |  |
| Population aged > 64 |  |  |  |
| Life expectancy at birth |  |  |  |
| Life expectancy at age 65 |  |  |  |

Note: Preferred sources: EUROSTAT, OECD, WHO

Data as of 31 December

Source:

## Organisation of the health care system

* Indicate the organisation of the health care system by indicating the type of health care system (National Health Service or Social Health Insurance), the main actors, the coverage and the main underlying law/decree.
* How is outpatient and in-patient health care organised?
* How is primary outpatient care practised? In outpatient clinics (“ambulatories”), by independent General Practitioners (GP), by specialists or other?
* How is in-patient care organised? Are private (profit or non-profit) or public hospitals dominating the system?
* How are outpatient doctors remunerated? Who are the main payers in the in-patient sector? In general, how are hospitals remunerated? Are private (for-profit/ non-profit) or public hospitals dominating the system?
* Give the trends in the evolution of number of doctors and pharmacists and discuss if it is sufficient to cover the country needs.

## Health expenditure

* Please complete Table 1.2 and comment on the trends regarding health expenditure (HE) in total by sector (outpatient and in-patient) and funding (private and public).

Table 1.2:  
Country – Health expenditure 2012, 2017, 2022

|  |  |  |  |
| --- | --- | --- | --- |
| Health expenditure  in NCU = \_\_\_\_\_\_\_1 | 2012 | 2017 | 2022 |
| GDP |  |  |  |
| THE |  |  |  |
| *- thereof public HE* |  |  |  |
| *- thereof private HE* |  |  |  |
| HE in the outpatient sector |  |  |  |
| *- thereof public* |  |  |  |
| *- thereof private* |  |  |  |
| HE in the in-patient sector |  |  |  |
| *- thereof public* |  |  |  |
| *- thereof private* |  |  |  |
| *Exchange rate (NCU per* €) |  |  |  |

GDP = gross domestic product, HE = health expenditure, NCU = national currency unit, THE = total health expenditure

1 Please indicate in which currency the data are provided.

Please provide, wherever possible, absolute figures; if not possible, you can provide the estimated share of public/private funding.

Note: Preferred sources: EUROSTAT, OECD, WHO or respectively for expenditure data EUROSTAT-OECD-WHO Joint SHA collection when available, or national sources  
For the international comparison please indicate which expenditure is included in the stated figures. Please state any limitation of the expenditure data.

Source:

## Sources of funding

* What is the main source of funding i.e. social health insurance contributions or general taxation? What is the current health expenditure as a percentage of the gross domestic product (GDP) and what is the public and private share of total health expenditure? What is the share for outpatient and in-patient health expenditure?
* Secondary sources of funding, e.g. voluntary health insurance (VHI) or out-of pocket payments (OPP) of patients. What is the role of VHI in your country? Please specify how much (in percentage) of the funds are financed through these secondary sources.

# Pharmaceutical system

This section provides a description of the pharmaceutical system; its organisation, regulatory framework and authorities, the market players and the funding of the system for the outpatient and the in-patient sectors as of 2023.

## Organisation of the pharmaceutical system

* Please describe the pharmaceutical system in your country as of 2023 and briefly explain the pharmaceutical policy in the in-patient and the outpatient sector. Please provide a flowchart of the pharmaceutical system following the model in Figure 2.1. If possible, develop a flow-chart integrating the in-patient sector, or providing two charts.

Figure 2.1:  
Country – Flowchart of the pharmaceutical system, 2023  
  
Kindly provide a graphical overview chart of the pricing and reimbursement system in your country. Consult the PPRI website at <https://ppri.goeg.at/methodology_documents> for Poster Templates.  
  
Country examples: <https://ppri.goeg.at/ppri_posters>

Source:

* Please fill out Table 2.1 giving information on the relevant authorities and key regulatory actors (including committees, boards, etc.) and third party payers as well as market actors and their interest associations as of 2023.

Table 2.1:  
Country – Legal basis and actors (authorities and market players) of the pharmaceutical system, 2023

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Fields | Legal basis | Scope (in-patient, outpatient sector) | Authorities in English  (local name,  local abbreviation) | Activity / responsibility in the pharmaceutical system | Actors and interest associations in English  (local name,  local abbreviation) |
| Market authorisation | e.g. Austrian Medicines Law | In- and outpatient sector | Federal Office for Safety in Health Care and AGES Medizinmarktaufsicht – Austrian Medicines and Medical Devices Agency (Bundesamt für Sicherheit im Gesundheitswesen (BASG) / AGES Medi­zinmarktaufsicht) | Responsible for marketing authorisation of medicinal products in Austria and assessment of medicinal products and medical devices which are already on the market regarding efficacy, adverse reactions, production, shipment and storage. | e.g. pharmaceutical companies  Interest associations: Pharmig – pharmaceutical industry association, FOPI (Forum der forschenden phamazeutischen Industrie) – association of research oriented manufacturers, Österreichischer Generikaverband (ÖGV) - generics industry associations |
| Pricing / Purchasing |  |  |  |  |  |
| Reimbursement |  |  |  |  |  |
| Promotion |  |  |  |  |  |
| Distribution |  |  |  |  |  |
| Vigilance |  |  |  |  |  |

Source:

* Please comment on the table.

## Availability of and access to medicines

* Please comment on the developments of availability of medicines in your country (e.g. number of authorised and medicines available on the market).
* Please fill in Table 2.2 and comment on the developments of prescriptions. Provide explanations, if available, on trends (e.g. rising prescriptions in value due to new medicines, decreasing number of prescriptions due to rational use). Please note that the data only refer to the outpatient sector. Should this not be the case in your country (e.g. total market) please indicate.

Table 2.2:  
Country – Annual prescriptions in the outpatient sector 2012, 2017, 2022

|  |  |  |  |
| --- | --- | --- | --- |
| Prescriptions | 2012 | 2017 | 2022 |
| No. of prescriptions (in volume) |  |  |  |
| Prescriptions in value  (in NCU = \_\_\_\_) |  |  |  |

Prescription in volume = number of items prescribed.  
Prescription in value = public expenditure of prescribed medicines.

Should you use different definitions, please indicate.

Source:

* What is the average time between marketing authorisation and patient accessibility defined as the medicines actually being available on the market? Please consider and comment on the different phases (time till having a price / granting reimbursement, time between reimbursement approval and actual launch of the product by the market authorisation holder).
* Please state the number of new molecular entities (NME) launched per year for the time frame 2012 – 2017 and 2017 – 2022 (if possible). Please fill out Table 2.3.

Table 2.3:  
Country – Number of new molecular entities, 2012-2022

|  |  |  |
| --- | --- | --- |
| New molecular entities | 2012 – 2017 | 2017 – 2022 |
| Number of new molecular entities |  |  |

Source:

## Development of the pharmaceutical sales

* Please give information about the development of the pharmaceutical sales and the share of the outpatient, in-patient and parallel traded market.

## Pharmaceutical consumption

* Please complete Table 2.4 and comment on it and explain the trends in the total pharmaceutical consumption and the consumption in the outpatient and in-patient sectors.
* Please especially comment on the common measurement for consumption (packs, DDD) in your country (outpatient, in-patient) and possible limitations. If there are limitations in surveying / collecting of consumption data, which measures are undertaken to overcome them? What is the legal basis?
* Please also comment on the availability of a system for statistic management of consumption data in the country for medicine in the outpatient and in-patient sector? When was it introduced and commissioned? Who manages and runs it? Is there an obligation to deliver the data? Can (all) hospitals provide consumption data? Is it possible to quantify pharmaceutical consumption by every department? Is it possible to link up pharmaceutical consumption with the patient (i.e. a given unit with a given patient or by an ATC code)? Is there a monitoring possibility?

Table 2.4:   
Country – Annual pharmaceutical consumption 2012, 2017, 2022

|  |  |  |  |
| --- | --- | --- | --- |
| Consumption | 2012 | *2017* | 2022 |
| Total pharmaceutical consumption | | | |
| In packs |  |  |  |
| In DDD |  |  |  |
| Pharmaceutical consumption in the in-patient sector | | | |
| In packs |  |  |  |
| In DDD |  |  |  |
| Pharmaceutical consumption in the outpatient sector | | | |
| In Packs |  |  |  |
| In DDD |  |  |  |

DDD = defined daily doses

Source:

## Generics

* Please complete Table 2.5 and comment on the relevance of generics in your country in general and particularly in the in-patient sector regarding the following questions:
* Are there any legal regulations regarding generics especially with regard to market authorisation and to pricing and reimbursement?
* Please comment on the relevance of the generic uptake/use in the in-patient sector with regard to the outpatient sector?

Table 2.5:   
Country – Development of the generic shares in volume and value, 2012, 2022

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Generic share | Volume1 | | Value2 | |
| 2012 | 20223 | 2012 | 20223 |
| Shares in % of total market (in-patient/ outpatient) |  |  |  |  |
| Shares in % of total outpatient market |  |  |  |  |
| Shares in % of outpatient reimbursement market |  |  |  |  |
| Shares in % of outpatient off-patent market |  |  |  |  |
| Shares in % of the in-patient market |  |  |  |  |

1 Expressed in number of prescriptions (if you have another measure for volume e.g. medicines/packs dispensed or sold please specify)

2 Expressed in expenditure (if you have another measure for value e.g. sales, please specify)

3 If you provide data before 2022, please indicate the year

Source:

## Top 10 medicines

* Could you please fill in and comment on Table 2.6 and Table 2.7 indicating the Top 10 active ingredients (indicating their ATC code in a separate column) in volume and in value for your country.

Table 2.6:  
Country – Top 10 active ingredients in value and volume in the outpatient sector, 2022

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Position | Top active ingredients used in the outpatient sector, ranked with regard to consumption | | Position | Top active ingredients used in the outpatient sector, ranked with regard to expenditure | |
| 1 |  |  | 1 | B03XA01 | Erythropoietin |
| 2 |  |  | 2 |  |  |
| 3 |  |  | 3 |  |  |
| 4 |  |  | 4 |  |  |
| 5 |  |  | 5 |  |  |
| 6 |  |  | 6 |  |  |
| 7 |  |  | 7 |  |  |
| 8 |  |  | 8 |  |  |
| 9 |  |  | 9 |  |  |
| 10 |  |  | 10 |  |  |

Source:

Table 2.7:  
Country – Top 10 active ingredients in value and volume in the inpatient sector, 2022

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Position | Top active ingredients used in the in-patient sector, ranked with regard to consumption | | Position | Top active ingredients used in the in-patient sector, ranked with regard to expenditure | |
| 1 | B05BB01 | Sodium | 1 |  |  |
| 2 |  |  | 2 |  |  |
| 3 |  |  | 3 |  |  |
| 4 |  |  | 4 |  |  |
| 5 |  |  | 5 |  |  |
| 6 |  |  | 6 |  |  |
| 7 |  |  | 7 |  |  |
| 8 |  |  | 8 |  |  |
| 9 |  |  | 9 |  |  |
| 10 |  |  | 10 |  |  |

Source:

## Market players

* Please give an overview on the market players, including the pharmaceutical industry, wholesalers, and retailers.
* Who is allowed to dispense medicines? E.g. community pharmacies, dispensing doctors, mail-order / internet pharmacies, other dispensaries (e.g. drug stores, supermarkets).
* Which products are the various dispensaries allowed to dispense? Full assortment of medicines (POM and NPM)? Other products (under what regulations)? Only selected range of NPM?
* Please complete Table 2.8 and comment on it, and describe the role of community pharmacies in the delivery chain in your country with regard to ownership (privately/publicly owned), allowance of chains, potential vertical integration of wholesalers and pharmacies, different distribution chains (pharmacy outlets, POM dispensing doctors, hospital pharmacies dispensing to outpatients etc.) For community pharmacies and other POM dispensaries, please indicate the total number and the number per 1,000 inhabitants.

Table 2.8:  
Country – Retailers of medicines 2012, 2017, 2022

|  |  |  |  |
| --- | --- | --- | --- |
| Retailers | 2012 | 2017 | 2022 |
| No. of community pharmacies1 |  |  |  |
| * *Thereof: No. of private pharmacies2* |  |  |  |
| * *Thereof: No. of public pharmacies* |  |  |  |
| No. of hospital pharmacies for outpatients |  |  |  |
| No. of dispensing doctors |  |  |  |
| No. of other POM disp.,  *please specify* |  |  |  |
| **Total no. of POM dispensaries** |  |  |  |
| No. of internet pharmacies |  |  |  |
| No. of NPM disp., like drugstores |  |  |  |

Disp. = dispensaries, No. = number, NPM = non-prescription medicines, POM = prescription-only medicines

POM dispensaries are facilities that are allowed to sell POM to outpatients (Glossary on pharmaceutical terms of the Vienna WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies available at <http://ppri.goeg.at>).

1 hospital pharmacies dispensing to outpatients are not included in this figure (according to the Glossary on pharmaceutical terms of the Vienna WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies available at <http://ppri.goeg.at>).

2 Private pharmacies are pharmacies owned by private persons or entities; public pharmacies are in public ownership.

Data as of 1 January

Source:

* Please shortly explain the role of hospital pharmacies: Do all hospitals have a pharmacy? Do they only serve patients inside the hospital or are they allowed to dispense medicines to outpatients? Do hospital pharmacies also run a community pharmacy for outpatients on the hospital’s premises, or are community pharmacies separate from the hospital pharmacy allowed to be established on the premise of the hospital?

## Pharmaceutical expenditure

* Please complete Table 2.9 and comment in particular on status and trends regarding pharmaceutical expenditure in total and by payer (public/private) in the in-patient and the outpatient sector:

Table 2.9:  
Country – Total pharmaceutical expenditure 2012, 2017, 2022

|  |  |  |  |
| --- | --- | --- | --- |
| Pharmaceutical expenditure | 2012 | 2017 | 2022 |
| TPE in NCU = \_\_\_\_\_\_\_1 |  |  |  |
| * *thereof public* |  |  |  |
| * *thereof private* |  |  |  |
| PE in the outpatient sector |  |  |  |
| * *thereof public* |  |  |  |
| * *thereof private* |  |  |  |
| PE in the in-patient sector |  |  |  |
| * *thereof public* |  |  |  |
| * *thereof private* |  |  |  |

NCU = national currency unit, PE = pharmaceutical expenditure, TPE = total pharmaceutical expenditure

1 Please indicate in which currency the data are provided. Please use national currency.

Please provide, wherever possible, absolute figures; if not possible, you can provide the estimated share of public/private funding.

Data as of 31 December

Note: Preferred sources: EUROSTAT-OECD-WHO Joint SHA collection when available, or national sources.

For the international comparison please indicate which expenditure is included in the stated figures (e.g. if expenditure data cover just medicines or also medical durables and non-durables). Please state any limitation of the expenditure data.

Source:

## Sources of funding

* Give an overview of the sources of funding (public and private) of medicines in the outpatient and in-patient sector.

# Pricing, reimbursement and volume control in the outpatient sector

This section covers a description of the organisation of the pricing system and policies. It describes also the organisation of the reimbursement system, the reimbursement schemes, reference price system, private pharmaceutical expenses and the volume control mechanisms in the outpatient sector as of 2023.

## Organisation of the outpatient sector

* What is the legal framework in 2023 and who are the main actors in pricing of medicines and what responsibilities do these actors have?

## Pricing of medicines

### Pricing policies

* Describe the main pricing policies for medicines (free pricing, statutory pricing, price negotiations) in your country – with regard to the different types of medicines (prescription medicines / NPM, hospital medicines, innovative medicines, generics, reimbursable / non-reimbursable medicines). For definitions please consult the Glossary on pharmaceutical terms of the Vienna WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies available at <http://ppri.goeg.at>.
* Fill in Table 3.1 and please specify for which medicines the pricing policies are valid. Feel free to insert more rows, e.g. on “Price-Volume Agreements” or “Price Notification”.

Table 3.1:  
Country – Ways of pricing of medicines at manufacturer level, 2023

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Pricing policies | (Non) prescription market | | (Non) reimbursement market | | Specific groups of medicine | | |
| POM | NPM | Reimbursable | Non-reimbursable | Generics | Parallel imported | Others, specify: e.g. biosimilars |
| Free pricing |  |  |  |  |  |  |  |
| Statutory pricing |  |  |  |  |  |  |  |
| Price negotiations |  |  |  |  |  |  |  |
| Tendering |  |  |  |  |  |  |  |
| Others – specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |  |  |  |  |  |  |

POM = prescription-only medicine(s), NPM = non-prescription medicine(s)

How to fill in the table: Please fill in “Yes” or “No”, if this policy is applied. Feel free to add for further specifications, e.g. POM – yes, but only if reimbursable

Source:

### Pricing Policies

* Please complete [Table 3.2](#Table32) and comment on it:
* Which pricing policies are currently used?
* Are these enforced by law? Who is involved in the pricing policy?
* Have there been major changes in the pricing policy in the past few years?

Table 3.2:   
Country – Pricing policies, 2023

| Pricing policies | In use: yes / no | Price type1 | Scope2 |
| --- | --- | --- | --- |
| External price referencing |  |  |  |
| Internal price referencing |  |  |  |
| Cost-plus pricing |  |  |  |
| Indirect profit control |  |  |  |
| Managed-entry agreements, pls. specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |  |  |
| Others, specify: \_\_\_\_\_\_\_\_ |  |  |  |

1 Price type = the level (manufacturer, pharmacy purchasing, pharmacy retail) at which the price is set.

2 Scope = a pricing policy does not always refer to all medicines: e.g. a pricing policy could only refer to reimbursable medicines, whereas for NPM there is free pricing.

Source:

* Which criteria are taken into account in the pricing decision? Are there laws or other regulations for the different pricing policies?
* If possible, please explain the pricing policies in detail e.g.:
* External price referencing:
* Which countries are included in the basket for external price referencing? Why were these countries chosen? Are there alternative countries in case there are no data from the selected countries? What happens if there are no data from the selected countries?
* How are prices set? Please, explain the methodological background on how are prices set (at the average of all prices, the lowest price of the basket). Have there been changes in the methodology?
* Who provides the country price information? How is the data provided and in what way? In case a manufacturer provides the information, how does the authority check the information?
* What happens if the price in one of the reference countries changes?
* Internal price referencing:
* Are there formal rules (e.g. on methodology) or laws / decrees on internal price referencing? If yes, please explain.
* At which level (ATC 5 or below) are prices compared? Is there therapeutic referencing in your country? Have there been any changes in the methodology in the course of time?
* Cost-plus pricing
* Are there formal rules (e.g. on methodology) or laws / decrees on cost-plus pricing? If yes, please explain.
* Which evidence / information is required from the industry in the pricing policy? E.g. information on production cost, expected sales, price of the medicine in other countries, the therapeutic value, cost effectiveness analysis, any other information.
* (Indirect) profit control
* Are there formal rules (e.g. on methodology) or laws / decrees on cost-plus pricing? If yes, please explain.
* Tendering
* Do you apply tendering? If yes, please explain (for which medicines, procedural issues).
* Value-based pricing
* Do you apply value-based pricing as an integrated pricing and reimbursement policy? If yes, please elaborate how it work?
* If you do not use value-based pricing, please elaborate whether and how you include value-based elements in your pricing decisions?
* Managed-entry agreements
* Do you have managed-entry agreements? If yes, could you please elaborate: on the type of the agreement (performance-based, financial agreement, type of agreement, for which medicines), refer to section 3.4.5
* Others
* If there are other pricing policies, that play a role in the outpatient sector, please describe them.

### Specific pricing policies

Please write a section whether you have specific pricing policies

* For high-cost medicines: If yes, please elaborate (which is the definitions for the high-cost medicines, which pricing policies do you apply, specific procedural issues). Could you have any data on the impact on these policies (e.g. evaluations on savings).
* For generic and biosimilar medicines: Do you apply a generic price link (generic must be priced a specific percentage below the originator), or do have competition work (e.g. tendering)? Do your pricing policies differ for biosimilars from generics?

### Discounts / rebates

Please write a section on discounts and rebates, including the following points:

* Are there mandatory discounts in your country?
* If yes, for which medicines (e.g. medicines in the public interest)?
* Who is obliged to grant those mandatory discounts (e.g. manufacturer, distributor and other actors)?
* To whom (e.g. Social Insurance) have mandatory discounts to be granted?
* Which is the legal basis for granting mandatory discounts?
* Please state the amount of the mandatory discounts (for the different segments, to different actors, for different medicines) to be granted?
* Are all types of discounts / rebates allowed (or only cash discounts or also discounts in kind)?
* Are there specific rules (e.g. limitations) regarding commercial discounts / rebates (e.g. maximum limits for specific medicines, for specific actors)?
* In case of commercial discounts, please give the average for the different segments.

### Remuneration of wholesalers and community pharmacies

* Describe how wholesalers and community pharmacies are remunerated (mark-ups / fee-for service)? Is this regulated by law? If mark-ups are applied, are these linear, regressive, or other? Does the mark-up/mark-up regulation cover all medicines, or only the prescription / reimbursement segment? Do you have fee-for-service remuneration, e.g. for pharmacists? Could you please share the scheme with us?
* Please complete Table 3.3 and provide an overview of remuneration of wholesalers and pharmacists.

Table 3.3:  
Country – Regulation of wholesale and pharmacy remuneration, 2023

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Wholesale remuneration | | | Pharmacy remuneration | | |
|  | Regulation | Content | Scope\* | Regulation | Content | Scope\* |
| *Example* | *Yes* | *Regressive mark-ups* | *All  medicines* | *Yes* | *Regressive mark-ups / fee-for-service* | *All medicines* |
| *Your country* |  |  |  |  |  |  |

\* Regulations concerning mark-ups do not always apply to all medicines, it may also target only POM or reimbursable medicines

Source:

### Taxes

* What is the VAT rate on medicines?
* Is this the standard VAT rate or does the VAT applied to medicines differ from the normal VAT? Please indicate the relevant VAT rates in 2023: Standard VAT/ VAT on medicines.
* Please specify if the VAT refers only to a group of medicines and/or if there are split rates for different medicines e.g. reimbursable / non-reimbursable.
* Please, inform on changes in the VAT rates in the last few years (plus the reason for that) and on possible planned changes.
* Are there, as of 2023, further taxes / fees on medicines (e.g. a pharmacy fee per medicine dispensed or a general pharmacy tax like in Finland)?

## Reimbursement of medicines

### Reimbursement policies

* Describe the legal framework for the reimbursement policies? Who are the main actors in deciding the reimbursement of medicines, and what is their role? Which medicines (scope, e.g. also NPM products) are included in the reimbursement scheme?
* Please describe the general reimbursement scheme and, in case there are some, specific schemes (e.g. for specific patient groups or expensive medicines) by giving answers to the following points: What is the name of the current scheme? When was it introduced? What is the legal framework for this scheme? Who is covered by this scheme (coverage of population)? Who is excluded from this scheme (e.g. asylum seekers)?

### Reimbursement procedure

* How the reimbursement procedure is linked to pricing of medicines (e.g. pricing only for reimbursable medicines, access to reimbursement only after having been granted a price)?
* Does your country have positive or negative lists? If yes, how is this administered? Do(es) the list(s) contain active ingredients or medicines by trade name? How many active ingredients or medicines included in the list(s)? Are the lists published? If yes, please insert source. How often is (are) the list(s) updated? How often are changes in the list(s) made? How are these changes communicated to doctors, pharmacists and patients? Which evaluations are undertaken?
* Please elaborate further on the use of pharmaco-economics as criteria for inclusion and / or exclusion of medicines on the reimbursement list, if appropriate.
* Please explain the role and the composition of the responsible body. Who decides on the inclusion of medicines into reimbursement? Describe the criteria / factors that determine whether or not a pharmaceutical is eligible for reimbursement.
* Describe the relevant reimbursement categories and the reimbursement rates in your country. Who is in charge of defining these categories and which laws define and enforce these schemes? When were the regulations implemented?

### Reference price system

* Is there a reference price system in your country? When was the reference price system implemented?
* What is the scope (covering all products, limited rage)? Which products are covered? How many active substances and brands are included? Are parallel traded medicines included in reference groups?
* Which criteria are used to group medicines in categories (e.g. ATC 5 level, ATC 4 level, indication / disease)? Please explain in detail at what price type medicines are compared? How many reference groups are included? How often are reference price groups reviewed/updated and evaluated? What happens, if there are no matching medicines to compare with available in your country?
* How is the reference price calculated?
* As the lowest priced medicine in a group, as the average, as the average plus 10%, or as something else?
* Does your country have a reference price system where the reimbursement rate for all interchangeable substances (e.g. statins) is calculated from the lowest price or a computed price (e.g. the average of the two lowest-priced medicines, etc.)?
* What happens if a doctor prescribes a medicine above the reference price? Is the doctor allowed to do so? Does the patient have to pay the difference between the actual price and the reference price?
* Have there been major changes in the reference price system?

### Private pharmaceutical expenses

* Please describe the situation around the private pharmaceutical expenses. Which out-of-pocket payments (fixed co-payments, percentage payments, deductibles, etc.) are applied in your country? Explain which mechanisms and exemptions are in place for vulnerable groups?
* If possible, please insert a table showing the out-of-pocket payments in your country as shown in Table 3.2..

Table 3.4:  
Country – Out-of-pocket payments for medicines, 2023

|  |  |  |
| --- | --- | --- |
| Out-of-pocket payments | Amount | Vulnerable groups |
| Fixed co-payments |  |  |
| Percentage payments |  |  |
| Deductibles |  |  |
| Reference price system |  |  |

Source:

## Volume control

* Briefly describe the volume control measures in your country. Are there measures implemented to control the prescribing and use of medicines? E.g. obligatory budget constraints for prescribing doctors set by third party payer?
* Which generic and biosimilar policies are applied in your country? Are they mandatory or voluntary? How they are promoted?

### Generic substitution

Please elaborate on the developments and trends regarding generic substitution in your country as of 2023:

* Is generic substitution allowed in your country? Since when is generic substitution allowed in your country?
* Is generic substitution mandatory or voluntary? In case it is mandatory, please state the legal regulations for generic substitution.
* Is there a historic relevance of generics in your country?
* How is the public perception of generics in your country? Are doctors allowed to exclude generic substitution? If yes, under which prerequisites? Are pharmacists allowed to substitute a branded medicine (e.g. the originator) with a generic? Please explain the prerequisites for pharmacists to substitute e.g. it is mandatory or only allowed when the doctors has written the prescription with its International Non-proprietary Name (INN).
* Are there incentives in place for generic substitution? If yes, please explain which (e.g. financial incentives). In case of non-adherence, are there sanctions? Are pharmacists allowed to substitute therapeutically (i.e. dispense a pharmaceutical with equal therapeutic benefits (~ analogous substitution). Is this type of substitution obligatory? Are pharmacists allowed to substitute parallel imported medicines? Is this type of substitution obligatory?

### Biosimilar substitution

Please elaborate on the developments and trends regarding biosimilar substitution in your country as of 2023

* Is biosimilar substitution allowed in your country? Since when is biosimilar substitution allowed in your country?
* Is biosimilar substitution mandatory or voluntary? In case it is mandatory, please state the legal regulations for biosimilar substitution.
* Is there a historic relevance of biosimilars in your country?
* How is the public perception of biosimilars in your country? Are doctors allowed to exclude biosimilar substitution? If yes, under which prerequisites? “Are doctors allowed to switch patients that are already established on a biological medicine to a biosimilar?” Are pharmacists allowed to substitute a biological medicine (e.g. reference product) with a biosimilar? Please explain the prerequisites for pharmacists to substitute e.g. the authorized prescriber does not state that the prescription is to be dispensed only as directed.
* Are there incentives in place for biosimilar substitution? If yes, please explain which (e.g. financial incentives). In case of non-adherence, are there sanctions? Are pharmacists allowed to substitute parallel imported medicines? Is this type of substitution obligatory?

### INN prescribing

Please elaborate on the developments and trends regarding INN prescribing in your country as of 2023:

* Are doctors allowed to prescribe generically? Do doctors receive an evaluation of their prescribing habits? Is it mandatory, i.e. Do doctors have to prescribe by the International Non-proprietary Name (INN)? What happens if a doctor opposes to this?

### Other generic and biosimilar promotion

Please elaborate on the developments and trends regarding other generic promotion policies in your country as of 2023:

* Is the use of generic medicines promoted (e.g. among patients, doctors, pharmacists)? If yes, how and which measures are implemented (e.g. information campaigns).
* Are there special procedures to promote the use of generics and biosimilar such as lower prescription fees for generic and biosimilars s or fast track pricing and reimbursement decision or faster launch?

### Claw-backs and paybacks

Please elaborate on the developments and trends regarding claw-backs / paybacks in your country as of 2023:

* Are claw-backs and paybacks to public payer in place in your country? If yes, please explain. When was it introduced? What is the legal basis? When do actors have to pay, and to which extent? At which actors are the claw-backs targeted? What administrative arrangements and sanctions underpin these arrangements?

### Managed-entry agreements

Please elaborate on the developments and trends regarding risk-sharing schemes / managed entry agreements in your country in your country as of 2023:

* Do you have managed-entry agreements in your country?
* Are they common, or only applied in a few cases? (pls. provide some examples)
* Which types of MEA (financial schemes, performance-based agreement) do you have?
* What is the legal basis? Which actors / active ingredients / products / sectors (outpatient only or also in-patient?) are covered?
* Are results / evaluations available?

## Evaluation

* Briefly describe the methods used to evaluate the pharmaceutical prices, expenditure, prescriptions and consumption? If applicable, describe when these tools were implemented? Who is in charge of the monitoring process and at which frequency? Are there any written evaluations available?
* Please describe briefly the evaluation measures in your country as of 2023. When writing this paragraph, please consider the following points:
* Are health-economic evaluations necessary for type of medicines (all, POM, NPM) and are there any differences? Evaluation of pharmaco-economic guidelines:
* Please give an overview of the content of the pharmaco-economic guidelines.
* How often are the pharmaco-economic guidelines updated / revised?
* Who is in charge of the evaluation of the pharmaco-economic guidelines?
* Please provide a rough estimation on possible savings achieved from pricing, rational use or cost-containment strategies in medicines? Do you know other achievements concerning medicines (e.g. better compliance) due to these strategies?
* Do medicine shortages occur in your country? If yes, which products, sectors are concerned? What are the reasons for shortages and how do you deal with them in your country?

### Prescription monitoring

Please describe the developments and trends regarding prescription monitoring in your country as of 2023:

* Are there prescription guidelines (such as treatment guidelines) in your country in place? When was this measure implemented? Which authority / institution is in charge of the implementation? (E.g. government, universities, third party payers, research institutions, private industry / professional association research institutions? Many of these often produce annual reports, please provide the corresponding websites).
* What is the frequency of monitoring this measure? Are the results published? Please insert the link. Are there any specific indicators used? Please, comment and provide examples. Have there been any written evaluations of the policies? If yes, are the reports publicly available? If so, please add a link to the publication and the institution behind the publication.

### Pharmaceutical consumption monitoring

Please describe the developments and trends regarding monitoring of pharmaceutical consumption in your country as of 2023:

* Is pharmaceutical consumption monitored in your country (e.g. per region, per patient, per diagnosis)? When was this measure implemented?
* Which authority / institution is in charge of monitoring pharmaceutical consumption? (E.g. government, universities, third party payers, research institutions, private industry / professional association research institutions? Many of these often produce annual reports, please provide the corresponding websites). What is the frequency of monitoring this measure? Are the results published? Please insert link. Are there any specific indicators used? Please, comment and provide examples. Have there been any written evaluations of the policies? If yes, are the reports publicly available? If so, please add a link to the publication and the institution behind the publication.
* Are there computerised tracking systems for prescriptions in place? Are individual sizes of prescribed packages monitored? (Since in some countries physicians prescribe smaller size packages, which leads to higher cost for patients). Is the adherence to treatments monitored by monitoring the share of medicines actually dispensed

### Decision making tools

Please describe briefly the tools that are used in the decision-making process regarding medicines in your country as of 2023. When writing this paragraph, please consider the following points:

* Please state the legal national source for pharmaco-economic analyses. Since when are pharmaco-economic analyses applied? Who performs them? Is the provision necessary for obtaining market authorisation/ for the pricing decision/ to obtain reimbursement status?
* Are there Heath Technology Assessments (HTA) performed in your country (at national, regional and/or facility level) ? Are they used as a base for decision making? Are HTA appraisal processes embedded in national pricing and reimbursement policies?
* Are external audit reports available?
* Is your country involved in pre-launch activities, such as horizon scanning and forecasting? If yes, please elaborate (who is involved? Is there a systematic procedure e.g. with regard to reporting? Are the results published?

# Pricing, reimbursement and volume control in the inpatient sector

This section describes the organisation of the pricing system and policies in the hospital sector. It covers the reimbursement and the volume control and the reimbursement related cost-containing measures in the in-patient sector.

## Organisation of the in-patient sector

* What is the legal framework regarding pricing of medicines used in hospitals and who are the main actors in pricing of medicines and what responsibilities do these actors have?

## Pricing and purchasing policies

* At hospital level, who is in charge of deciding if and which price medicines are purchased? Are there specific institutions, bodies or persons involved in the process? What is the role of the hospital pharmacists?
* Which price type does the hospital price correspond to (ex-factory, pharmacy purchasing price, pharmacy retail price)? Is there an official price calculation scheme for medicines used in hospitals?
* Are medicines sold to hospitals subject to VAT and at which rate?
* Are mark-ups relevant for medicines used in hospitals? Please, describe the possible schemes. What is the legal basis?
* Are there any mandatory or voluntary (commercial) discounts, rebates or other price reductions granted to the hospitals?
* Please describe the major purchasing policies (e.g. tendering or negotiations) used in the in-patient sector in your country as of 2023. If different purchasing policies are applied in your country (in parallel or one following the other one), please comment on their relevance. Should one purchasing policy follow another one (e.g. first central tendering, then direct purchases of hospitals) please indicate.
* Are there other purchasing policies (besides tendering and negotiations) that play a role in the in-patient sector? What are the legal provisions for these? Who is involved and which are the most relevant criteria?
* Do you have managed-entry agreements in your country in hospitals? Are they common, or only applied in a few cases? (pls. provide some examples) Which types of MEA (financial schemes, performance-based agreement) do you have? What is the legal basis? Which actors / active ingredients / products /sectors (in-patient only or also outpatient?) are covered? Are results / evaluations available?

## Procurement

* Do hospitals carry out their own procurement or is there joint procurement for a group of hospitals? Is there a national / regional procurement agency in your country? How often does procurement take place?
* Who is involved in the procurement process? Who has advisory and who has decision taking role in the procurement process? Which are the most relevant criteria for deciding if a medicine is purchased?

## Reimbursement

Please describe in this section how medicines used in hospitals are financed in your country as of 2023. Specify if the financing/reimbursement system is applied country-wide or for a majority of hospitals (e.g. public hospitals). When describing the system, please consider the following points:

* Does financing/reimbursement in the inpatient sector differ from the outpatient sector? Which legal provisions (e.g. Social Insurance Law) are relevant for reimbursement in the hospital sector?
* Who is the main “payer” of medicines in hospitals (e.g., NHS / SHI, state, owner of hospital, community / region)? Is funding of medicines covered by hospital budgets? Which budgets cover reimbursement for medicines in in-patient care?
* Are there co-operative funding ways for the reimbursement of medicines (e.g. does NHS / SHI pay a share of the medicines used in hospitals like in the Netherlands)? If yes, please give an example for specific illnesses or medicines. Are there specific budgets provided for specific medicines used in hospitals (e.g. for orphan drugs, for specific diseases, for high cost medicines)?
* At what level are medicines covered by hospital budgets for in-patient care (fully or partly reimbursed)?
* Are the criteria for funding of medicines in the hospital sector any different from the general sector?
* Are positive and/or negative list(s) applied in the outpatient sector also relevant for the in-patient sector?

If medicines are partly reimbursed, please answer the following questions:

* Do patients have to co-pay for medicines received during the treatment in hospitals?
* If yes: Do all patients have to co-pay? Are there exemptions for vulnerable groups?
* Which are the prerequisites? Note:
* How much do they have to co-pay? And in which form?

### Hospital pharmaceutical formularies

Please describe if there are hospital pharmaceutical formularies in your country as of 2023. When describing the system, please consider the following points:

* Are there separate hospital pharmaceutical formularies for each hospital?
* Do hospitals (which? – all public hospitals, hospitals of the same owner?) have joint hospital pharmaceutical formularies?
* Are there country-national hospital and regional hospital pharmaceutical formularies, possibly accompanied by individual hospital formularies?

### Pharmaceutical and Therapeutic Committees

* What is the role of the hospital pharmacists and the pharmaceutical and therapeutic committees – advisory or decision taking?

## Volume Control in the in-patient sector

* Briefly describe the methods used to evaluate the pharmaceutical prices, expenditure, prescriptions and consumption? If applicable, describe when these tools were implemented? Who is in charge of the monitoring process and at which frequency? Are there any written evaluations available?

### Monitoring

This section provides an overview of the programmes and methods used to evaluate the pharmaceutical policies and system in the in-patient sector, and its impact on health, access to medicines, and cost-containment. It mainly focuses on monitoring of prices, pharmaceutical expenditure and consumption.

* Are prices in the in-patient sector regularly monitored? If yes, by whom?

Please describe the developments and trends regarding monitoring of pharmaceutical expenditure in your country as of 2023:

* Is pharmaceutical expenditure monitored in the in-patient sector in your country (e.g. per region, per patient, per diagnosis)? Is this monitoring done for each hospital or for groups of hospitals? (Please specify in which hospitals, e.g. public hospitals, hospitals of a specific owner)? Is it possible to quantify the expenditure of pharmaceuticals for a given disease, for instance via a DRG.
* When was this measure implemented?
* Which authority / institution is in charge of monitoring prices? (E.g. the individual hospital, the government, universities, third party payers, research institutions, private industry / professional association research institutions? How many of these often produce annual reports, please provide the corresponding websites. Are the results presented and discussed (in meetings of hospital pharmacists and the hospital management)?
* What is the frequency of monitoring this measure? Are the results published? Please insert the link.
* What is the role of the hospital pharmacists with regard to rational use and monitoring?
* Are there any specific indicators used? Please, comment and provide examples.
* Have there been any written evaluations of the policies? If yes, are the reports publicly available? If so, please add a link to the publication and the institution behind the publication.
* Are there any generic and biosimilar promotion policies in place?
* Do medicine shortages occur in your country? If yes, which products, sectors are concerned? What are the reasons for shortages and how do you deal with them in your country?

### Decision-making tools

Please describe briefly the tools that are used in the decision-making process regarding medicines in the in-patient sector in your country as of 2023. When writing this paragraph, please consider the following points:

* Which tools are used in decision making process regarding medicines in the in-patient sector? Describe the use of pharmaco-economic analysis? Who performs them?
* Are pharmaco-economic analyses also applied in the in-patient sector?
* Who performs the pharmaco-economic analyses?
* Is your country involved in pre-launch activities, such as horizon scanning and forecasting? If yes, please elaborate (who is involved? Is there a systematic procedure e.g. with regard to reporting? Are the results published?)

### Evaluation of measures

Please describe briefly the evaluation measures relevant in the in-patient sector in your country as of 2023. When writing this paragraph, please consider the following points:

* Are pharmaco-economic evaluations necessary for types of medicines (all, POM, NPM) and are there any differences?
* Evaluation of pharmaco-economic guidelines:
* Please give an overview of the content of the pharmaco-economic guidelines.
* How often are the pharmaco-economic guidelines updated / revised?
* Who is in charge of the evaluation of the pharmaco-economic guidelines?

### Reports and results

Please describe briefly the evaluation / assessment reports relevant in the in-patient sector in your country as of 2023. When writing this paragraph, please consider the following points:

* Are there Health Technology Assessments (HTA) performed in your country? Are the HTA published? Do the HTA build the basis for decision-making?
* Are external audit reports available?

### Interface management

Please describe the relevance of interface management (i.e. mechanisms of co-operation between in-patient and outpatient sector) considering the following issues:

* Need for interface management: Please comment on the impact of pharmaceutical use in hospitals on the outpatient sector.
* Interface management: In terms of pharmaceutical care, how is interface management (in-patient/outpatient care) organised? Please provide some examples (good practice) of interface management?

# Developments

Please **Fehler! Verweisquelle konnte nicht gefunden werden.**briefly explain the most important changes in the outpatient and the inpatient sectors as well as the foreseen pharmaceutical reforms. Please, describe the systemic changes under implementation and those still under discussion.

Table 5.1:  
Most important changes in the outpatient and inpatient sectors from 2012 onwards

|  |  |  |
| --- | --- | --- |
| Year | Outpatient sector | Inpatient sector |
| 2012 |  |  |
| … |  |  |
|  |  |  |
|  |  |  |

# Bibliography

## Literature

Please include key references to relevant publications relating to your country used as sources of information within the PPRI Pharma Profile. The template of the PPRI Pharma Profile uses the Vancouver referencing system whereby citations are made within the text in parentheses, e.g. “(GÖG 2020)”, and the full references are listed alphabetically in this section.

Examples:

*Studies / Books:*

Vogler S, Zimmermann N, Dedet G, Lam J, Pedersen HB.: Pharmaceutical Pricing and Reimbursement Systems in Eastern Europe and Central Asia. WHO Regional Office for Europe, Copenhagen, 2020. Available at: <https://www.euro.who.int/__data/assets/pdf_file/0007/455938/Pharmaceutical-pricing-eng.pdf>

Vogler S, Haasis M.A., Zimmermann N.: PPRI Pharma Brief: Austria 2019. Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series. Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute), Vienna, 2019. Available at <https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PPRI_Pharma_Brief_AT_2019_October2020_final.pdf>

Vogler S, Zimmermann N, Haasis MA.: [PPRI Report 2018 - Pharmaceutical pricing and reimbursement policies in 47 PPRI network member countries](https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PPRI%20Report2018_2nd_edition_final.pdf). WHO Collaborating Centre for Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute), Vienna, 2019. Available at: <https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PPRI%20Report2018_2nd_edition_final.pdf>

Vogler S, Haasis MA, Dedet G, Lam J, Pedersen HB. Medicines reimbursement policies in Europe. WHO Regional Office for Europe, Copenhagen, 2018 Available at: <https://www.euro.who.int/__data/assets/pdf_file/0011/376625/pharmaceutical-reimbursement-eng.pdf?ua=1>

HiT 2018  
European Observatory on Health Care Systems and Policies 2018  
Health Care Systems in Transition. Austria 2018

*Journal articles:*

Vogler S, Fischer S.: [How to address medicines shortages: Findings from a cross-sectional study of 24 countries](https://www.sciencedirect.com/science/article/pii/S0168851020302256). Health Policy 2020; 124(12): 1287-1296

Vogler S, Zimmermann N, de Joncheere K.: Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015. Health Policy, 120, Issue 12: 1363–1377, 2016

*Book chapter:*

Vogler S, Schneider P, Panteli D, Busse R.: Biosimilars in Deutschland und im europäischen Vergleich – Marktsteuerungsmechanismen und Einsparpotenziale. In: Schwabe U, Ludwig W-D, Eds. Arzneiverordnungs-Report 2020. Berlin, Heidelberg: Springer; 2020.

## Legislation

Please list any legislation that is relevant for the PPRI Pharma Profile regarding your country’s pharmaceutical system.

## Web links

Please list any relevant web links for further reading on your country’s pharmaceutical system.